Suppr超能文献

小细胞肺癌的预后免疫组化标志物:综述。

Prognostic immunohistochemical markers for small cell lung cancer: A review.

机构信息

Department of Pathology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, PR China.

Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, PR China.

出版信息

Pathol Res Pract. 2021 Jan;217:153311. doi: 10.1016/j.prp.2020.153311. Epub 2020 Dec 4.

Abstract

BACKGROUND

Small Cell Lung Cancer (SCLC) is one of the most aggressive thoracic malignancies and has been very challenging in developing personalized medicine. While immunohistochemistry (IHC) markers have established role in pathology diagnosis of SCLC, it is particularly important to apply early and simple methods to effectively determine the prognosis. This study aimed to review and identify prognostic protein markers that have potential to be incorporated into clinical care for SCLC.

METHODS

we systematically reviewed PubMed, Embase, Web of Science and Cochrane Library until October 19th, 2019 that reported prognostic IHC markers in SCLC. In this review, we focused on markers evaluated in at least two independent studies to compile the most forthcoming prognostic markers.

RESULTS

According to their function in the tumor, including proliferation-related markers, growth suppression-related markers, invasion- and metastasis-related markers, apoptosis-related markers, angiogenesis-related markers, immune regulation-related markers. Extensive reports into informative tables based on sufficiencies of evidence were summarized as some easy-to-use literature reservoirs for further referring.

CONCLUSIONS

Strong evidence supports that the 24 emerging markers or their combinations may be useful in predicting prognosis, helping personalized therapy decision-making for SCLC patients.

摘要

背景

小细胞肺癌(SCLC)是最具侵袭性的胸部恶性肿瘤之一,在制定个性化治疗方案方面极具挑战性。免疫组织化学(IHC)标志物在 SCLC 的病理学诊断中具有重要作用,但应用早期、简单的方法来有效确定预后尤为重要。本研究旨在回顾并确定有潜力纳入 SCLC 临床治疗的预后蛋白标志物。

方法

我们系统地检索了 PubMed、Embase、Web of Science 和 Cochrane Library 数据库,检索时间截至 2019 年 10 月 19 日,检索内容为报道 SCLC 中具有预后意义的 IHC 标志物的研究。本综述重点关注在至少两项独立研究中评估过的标志物,以汇总最有前途的预后标志物。

结果

根据其在肿瘤中的功能,包括增殖相关标志物、生长抑制相关标志物、侵袭和转移相关标志物、凋亡相关标志物、血管生成相关标志物和免疫调节相关标志物。我们根据证据充分性将大量报告总结到信息表格中,为进一步参考提供了易于使用的文献资源库。

结论

大量证据支持,24 种新兴标志物或其组合可能有助于预测预后,为 SCLC 患者的个体化治疗决策提供帮助。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验